Novo Nordisk's Alzheimer Setback Intensifies Focus on Core GLP-1 Battle

Novo Nordisk shares are caught in a severe downdraft, with the stock down more than 45% year-on-year and a deeply oversold RSI reading of 19.5. This pressure stems from a dual challenge: the collapse of a key pipeline diversification effort and an intensifying price war in its core metabolic disease business. The company's attempt to expand the use of semaglutid beyond diabetes and obesity into Alzheimer's disease has ended in failure, forcing a strategic retreat just as competitive threats mount.

The definitive blow came from the Phase 3 EVOKE and EVOKE+ trials. After 104 weeks, oral semaglutid demonstrated no clinical benefit on cognition or daily function compared to a placebo in 3,808 patients with early-stage Alzheimer's. While researchers noted an approximate 10% reduction in disease-specific biomarkers in cerebrospinal fluid, analysts deemed the effect too marginal for patient benefit. Consequently, management has terminated the entire program, closing a promising avenue for growth outside metabolic disorders.

With the neurology pathway now blocked, Novo Nordisk is doubling down on its GLP-1 franchise with new commercial and logistical maneuvers. In Europe, the company secured a critical regulatory win last Thursday. The EMA now permits Wegovy to be transported at room temperature (up to 30°C) for up to 48 hours, eliminating the strict cold-chain requirement. This change drastically cuts logistical complexity and cost for pharmacies and online delivery services, potentially accelerating the expansion of direct-to-patient channels across the continent.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Simultaneously, the firm is pushing a higher-dose version of Wegovy in the United States. A new 7.2 mg dose is now available through over 70,000 US pharmacies and select telehealth providers. Late-stage trial data underpins the launch, showing about 89% of patients achieved at least a 5% weight loss over 72 weeks. To remain competitive, Novo Nordisk has set a cash-pay price of approximately $399 per month for this formulation.

These efforts are a direct response to growing competitive pressure, particularly from rival Eli Lilly. Lilly's recently launched oral GLP-1 drug, Foundayo, targets the same patient demographic. Furthermore, reports of emerging semaglutid generics in international markets contribute to sustained pricing pressure. This difficult environment is reflected in the company's own guidance, which forecasts a currency-adjusted decline in both sales and operating profit of 5% to 13% for 2026, citing lower realized prices and Medicaid coverage cuts for obesity treatments in the US.

To support shareholders during this transition, Novo Nordisk is accelerating its share buyback program. A partial tranche of up to 3.8 billion Danish kroner is allocated for repurchases through early May. The next major update on the company's financial health and pipeline progress, including the experimental triple-agonist UBT251, will come with the release of first-quarter 2026 results in May. That report will serve as a crucial indicator of whether operational advances in logistics and new doses can offset the broader erosion of prices.

Ad

Novo Nordisk Stock: New Analysis - 13 April

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69136516 |